Investor Alert

March 29, 2022, 6:01 a.m. EDT

GABY Inc.'s Mankind Dispensary is Named to Leafly's 2022 List of Best Rated Dispensaries in California

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    GABY Inc. (GABY)

or Cancel Already have a watchlist? Log In

Mar 29, 2022 (ACCESSWIRE via COMTEX) -- Mankind Is Recognized for Its Top-Rated Customer Service and Industry-Innovating "No Glass Barriers" Retail Experience

SAN DIEGO, CA / ACCESSWIRE / March 29, 2022 / GABY Inc. ("GABY" or the "Company") /zigman2/quotes/207479053/delayed CA:GABY +100.00% (otcqb:GABLF), a California consolidator of cannabis dispensaries and the parent company of San Diego's Mankind Dispensary ("Mankind"), is proud to announce that Mankind has been recognized as one of the top 20 dispensaries in California by Leafly and Leafly's more than 120 million yearly digital visitors.

Leafly's annual list of top dispensaries recognizes Mankind both for its top-rated customer service and budtender knowledge and for its "no glass barriers" approach to cannabis.

"Mankind Dispensary believes customer knowledge is power, so the budtenders there are always ready to help customers understand the details of the medicine they're getting and how it works…" the article proclaims. "Leafly reviews tend to agree - more than 1,100 of them have rated Mankind, with a near-perfect score."

This recognition comes on the heels of several notable milestones for Mankind, including, being named to Inc Magazine's list of 5,000 fastest growing companies, the dispensary celebrating one-million customers served with a massive four-day event, and being honored as a top dispensary in the 2021 Best of Weedmaps awards.

"It's remarkable to see Mankind's reputation continue to grow as one of the top dispensaries in all of California," said GABY Inc. Founder and CEO Margot Micallef. "This recognition from Leafly further solidifies what cannabis consumers from all walks of life across Southern California and beyond already know - if you want the best cannabis experience possible, come to Mankind."

Mankind will continue to build upon its reputation throughout 2022 and beyond with special events, exclusive product drops, community and social impact projects, and improved access to the best cannabis from across the state for the dispensary's medical and recreational customers.

Mankind License Number: C10-0000494-LIC. 21+ Recreational. 18+ Medical.

About GABY Inc.

GABY Inc. is a California-focused retail consolidator and the owner of Mankind Dispensary, one of the oldest licensed dispensaries in California. Mankind is a well-known, and highly respected dispensary with deep roots in the California cannabis community operating in San Diego, California. GABY curates and sells a diverse portfolio of products, including its own proprietary brands, Lulu's™ and Kind Republic™ through Mankind, manufactures Kind Republic, and distributes all its proprietary brands through its wholly owned subsidiary, GABY Manufacturing. A pioneer in the industry with a multi-vertical retail foundation, and a strong management team with experience in retail, consolidation, and cannabis, GABY is poised to grow its retail operations both organically and through acquisition.

GABY's shares trade on the Canadian Securities Exchange ("CSE") under the symbol "GABY" and on the OTCQB under the symbol "GABLF". For more information on GABY, visit GABYInc.com


Media Contact:
Senior Communications Manager
Charlie Rohlfs

Margot Micallef, Founder & CEO
or Investor Relations at IR@GABYinc.com

Disclaimer and Forward-Looking Information

The CSE does not accept responsibility for the adequacy or accuracy of this release. Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of the Company. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward-looking statements include, but are not limited to, the Company's future business strategy, including its plans to expand organically and through future acquisitions and the Company's anticipated benefits from its engagement with Hybrid Financial. Although GABY believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because GABY can give no assurance that they will prove to be correct. By its nature, such forward-looking information is subject to various risks and uncertainties, which could cause the actual results and expectations to differ materially from the anticipated results or expectations expressed. Without limitation, these risks and uncertainties include: the severity of the COVID-19 pandemic; risks associated with the cannabis industry in general; failure to benefit from partnerships or successfully integrate acquisitions; actions and initiatives of federal, state and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; the size of the medical-use and adult-use cannabis market; competition from other industry participants; adverse U.S., Canadian and global economic conditions; failure to comply with certain regulations; and departure of key management personnel or inability to attract and retain talent. GABY undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Each of Mankind and GABY Manufacturing, are subsidiaries of GABY and hold a cannabis license in the State of California. Readers are cautioned that unlike in Canada which has Federal 032320-F legislation uniformly governing the cultivation, distribution, sale and possession of medical cannabis under the Cannabis Act (Federal), in the United States ("U.S."), cannabis is largely regulated at the State level. Cannabis is legal in the State of California; however, cannabis remains illegal under U.S. federal laws. Notwithstanding the permissive regulatory environment of cannabis at the State level, cannabis continues to be categorized as a controlled substance under the Controlled Substances Act in the U.S. and as such, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. To the knowledge of the Company, the businesses operated by each of GABY's subsidiaries are conducted in a manner consistent with the State law of California, as applicable, and are in compliance with regulatory and licensing requirements applicable in the State of California, respectively. However, readers should be aware that strict compliance with State laws with respect to cannabis will neither absolve GABY, or its subsidiary of liability under U.S. federal law, nor will it provide a defense to any federal proceeding in the U.S. which could be brought against any of GABY, or its subsidiary. Any such proceedings brought against GABY, or its subsidiary may materially adversely affect the Company's operations and financial performance generally in the U.S. market specifically.



Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

CA : Canadian Securities Exchange
$ 0.01
+0.0050 +100.00%
Volume: 30,001
Dec. 5, 2022 3:14p
P/E Ratio
Dividend Yield
Market Cap
$3.56 million
Rev. per Employee

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.